Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2025 08:00 ET | Source: InvestorBrandNetwork (IBN)

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc.

AUSTIN, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
September 19, 2025 08:30 ET | Source: InvestorBrandNetwork (IBN)

NetworkNewsAudio Announces Audio Press Release (APR) on Innovation in Cancer, Rare Disease Treatment Space

AUSTIN, Texas, Sept. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market...
September 12, 2025 11:51 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline

AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing...
September 10, 2025 08:30 ET | Source: InvestorBrandNetwork (IBN)

IBN Initiates Coverage of Oncotelic Therapeutics Inc.

AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy...
August 28, 2025 09:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad Intellectual Property Contributions to Biopharma Industry

Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:...
July 17, 2025 11:08 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS, Calif., July 17, 2025 (GLOBE...
June 25, 2025 07:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based...